Malin reports intrinsic equity value of €9.36 per share at June 30

Malin Corporation plc, a stock listed on Euronext Growth Dublin, forecasted an intrinsic equity value of €9.36 per share as of June 30, 2026, and an estimated €8.28 per share by August 24, 2026. This data was unveiled in a press release on Tuesday.

The company's total intrinsic equity value saw an increase from €39.9 million as of December 31, 2025, to €40.7 million on June 30, 2026. The rise was mainly due to foreign exchange fluctuations and the adjustment of discount rates resulting from the passage of time.

However, the intrinsic equity value per share decreased by 12% to €8.28 at August 24, 2026, from the June 30 figure. This decline was attributed to a drop in the fair value of Kymab and a slight reduction in cash resulting from typical business operations.

Malin's cash position was €11.6 million as of June 30, 2026, a decrease from €12.9 million at December 31, 2025, and further down to approximately €11.2 million by August 24, 2026. The company's corporate cash operating expenses for the first half of 2026 were €0.8 million.

Malin has contingent value rights (CVRs) linked to the sale of Poseida to Roche. The company owns about 12% of Poseida and received a significant upfront payment of approximately $106.5 million in January 2025, with potential additional earnings up to $47.3 million under certain conditions.

Sanofi recently disclosed the termination of Amlitelimab's clinical development for moderate to severe atopic dermatitis. In response, Malin plans to set its valuation of its remaining stake in Kymab's contingent consideration to zero in the second half of 2026.

Additionally, Malin is collaborating with other investors in Viamet on a potential restructuring that could involve a direct investment in Mycovia. This report was crafted with the assistance of AI and later reviewed by an editor. For more details, refer to the Terms and Conditions.